Mirum Pharmaceuticals, Inc. - common stock — Quarterly Cash Flow (NASDAQ:MIRM) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 690.25 M725.83 M785.12 M842.81 M890.92 M1.04 B Total liabilities 456.99 M470.67 M493.07 M528.12 M648.42 M1.06 B Total equity 233.26 M255.16 M292.05 M314.69 M242.49 M-10.42 M Total liabilities & shareholders' equities 690.25 M725.83 M785.12 M842.81 M890.92 M1.04 B Total debt 308.51 M308.93 M309.37 M309.8 M310.25 M750.08 M Net debt 30.84 M4.38 M-66.18 M-73.53 M-76.01 M311.79 M

News

Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know

Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised

Insmed Catapults 30%, Leading A Biotech Rally. But Mirum Takes A Bath.

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript

Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates

Profitable Biotechs Strut Their Stuff As Stock Market Stumbles

Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead (NASDAQ:VIR)

Valero, Marathon, Other Oil Firms Defy Weak Market, Hit Record Highs, Lead 21 Onto Best Stock Lists

Stocks To Watch: 14 Names Test And Tease New Buy Zones

SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn (NYSEARCA:SBIO)

Mirum Pharmaceuticals: This Liver Disease Juggernaut Broadened Its Portfolio (NASDAQ:MIRM)